Since the beginning of the 20th century, dividend stocks have accounted for 75% of the total returns in the U.S. stock market. Dividend growth stocks, which are companies that regularly increase their cash payouts to shareholders annually, have significantly outperformed the majority of other asset classes over this 124-year span.The primary reason for this is the power of compounding. By owning a dividend growth stock and reinvesting the dividends each quarter, your investment can experience exponential gr ...

-   Global license and collaboration agreement to focus on the development of OSE-230, a monoclonal antibody designed to resolve chronic inflammation -   OSE Immunotherapeutics to receive an upfront payment of $48 million and will be eligible to receive up to an additional $665 million in milestone payments NORTH CHICAGO, Ill. and NANTES, France, Feb. 28, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, toda ...

epcoritamab-bysp - AbbVie宣布美国FDA已对epcoritamab-bysp的补充生物制品许可申请进行了优先审查[1] - epcoritamab-bysp将成为首个用于治疗成人R/R FL的皮下双特异性抗体，标志着其第二个适应症[1] - epcoritamab是AbbVie和Genmab共同开发的，旨在成为核心淋巴瘤治疗药物[3] - EPCORE™ NHL-1试验评估了epcoritamab在治疗复发性或难治性FL患者中的疗效和安全性[5] - epcoritamab已在全球获得批准用于治疗特定类型的大B细胞淋巴瘤，但在FL患者中的使用尚未获得批准[7] - Genmab和AbbVie正在评估epcoritamab在不同治疗方案中的使用，包括作为单药疗法和联合疗法[8] 患者治疗 - 美国患有弥漫性大B细胞淋巴瘤和滤泡性淋巴瘤的患者的经济负担和治疗模式[32] - 滤泡性淋巴瘤患者在利妥昔单抗时代的每次复发后，反应持续时间和生存时间缩短[34] 新疗法研究 - DuoBody-CD3xCD20在临床模型中诱导恶性B细胞的强效T细胞介导杀伤，并提供皮下给药的机会[35]

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. The FDA grants Priority Review to investigational ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. ("Cosette") announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for the first generic version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity. Cosette will imminently commence commercial shipments, triggering the 180 days exclusivity. Apurva Saraf, President and CEO of Cosette Pharma, stated, "This is a pivotal product appr ...

Collaboration to leverage AbbVie's therapeutic area expertise and Tentarix's Tentacles™ platform, to develop novel multifunctional biologics against one target in oncology and another in immunology AbbVie will receive an exclusive option to acquire the therapeutic programs following candidate nomination by Tentarix NORTH CHICAGO, Ill. and SAN DIEGO, Feb. 22, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and de ...

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that m ...

AbbVie (ABBV) announced that its current president and chief operating officer, Robert A. Michael, has been appointed as the new chief executive officer (CEO). The board unanimously selected Robert Michael to succeed Richard A. Gonzalez, who is retiring from his role as CEO after serving in this capacity since AbbVie was formed in 2013. AbbVie came into existence on Jan 1, 2013, after Abbott Laboratories divested its pharmaceutical division. Gonzalez will become executive chairman of the board of directors, ...

女性创业者支持计划 - BOTOX® Cosmetic x IFundWomen合作旨在消除自信差距，支持女性创业者[1] - 通过资助、指导和社区支持，帮助女性创业者实现梦想，克服自信差距[2] - 创业者面临着燃尽风险，女性创业者的燃尽问题自2019年以来增加了一倍以上[3] 资助计划细节 - 上一届BOTOX® Cosmetic资助计划的受益者表示计划对其业务和生活产生了巨大影响[4] - 每位企业家将完成为期十周的众筹辅导加速器计划，获得各种业务主题的专家指导和启动众筹活动的辅导[5] - 女性创业者可以申请BOTOX® Cosmetic x IFundWomen资助计划，截止日期为2024年3月19日[6] 资助计划进展 - BOTOX® Cosmetic将在今年春季公布资助获得者名单，继续关注女性创业者的故事[7]

Test tubes are seen in front of a displayed AbbVie logo in this illustration taken on May 21, 2021.AbbVie on Tuesday said longtime executive Robert Michael will become the company's new CEO, replacing Richard Gonzalez. Michael, who is AbbVie's president and chief operating officer, will become the company's second-ever CEO on July 1. Gonzalez, who has led the company since it spun out from Abbott Laboratories in 2013, will retire and become AbbVie's executive chairman. The announcement marks an end to Gonza ...